After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...

Novartis has made a takeover approach for rare disease-focused biotech Avidity Biosciences, as Big Pharma continues to hunt for deals to offset looming patent cliffs, according to people familiar with ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Citi wrote that concerns regarding Entresto going generic in the US may start fading away as the company continues to supply ...

The company is expected to remain a critical API supplier for Entresto, which is the single-largest product in its Custom Synthesis portfolio.

Shares of Avidity Biosciences RNA have soared 36% in the past month, all thanks to a report issued by the Financial Times (FT ...

Divis Laboratories rose 1.94% to Rs 6143.35 after a foreign broker reiterated its 'buy' rating on the stock with a price target of Rs 7,750, citing attractive valuations and supportive sector ...

Novartis AG said an experimental medicine helped patients with an autoimmune disease in late-stage studies, offering a boost for the Swiss drugmaker’s efforts in the field.

The Swiss pharmaceutical company is bracing for the patent expiration--and the arrival of generic competitors--for its heart drug Entresto, the group's best-selling medicine, at a time investors ...